AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Last trade$55.08
Day change-$0.23 (-0.42%)
Day range$54.89 – $56.82
Volume342,313
Market cap$2.82B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.82B
Price / earnings
189.24×
Price / book
5.28×
Price / sales
4.78×
EV / sales
4.56×
EV / EBITDA
70.44×
Profitability
Earnings per share
$0.29
Return on assets
2.07%
Return on equity
2.79%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.11×
Current ratio
4.33×
Quick ratio
3.29×
Cash ratio
2.23×
Cash flow
Price / cash flow
41.09×
Price / free cash flow
53.2×
Free cash flow
$52.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ATRC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$154.45M
$153.6M
$141.25M
$140.5M
$134.27M
$136.14M
$123.62M
$124.28M
Cost of revenue
$35.1M
$34.98M
$31.94M
$35.16M
$32.94M
$34.66M
$30.99M
$31.66M
Gross profit
$119.35M
$118.63M
$109.31M
$105.34M
$101.33M
$101.48M
$92.63M
$92.62M
Selling, general and administrative
$82.88M
$82.56M
$84.55M
$78.34M
$78.23M
$78.39M
$76.05M
$72.19M
Research and development
$32.12M
$26.4M
$24.24M
$24.51M
$22.89M
$29.28M
$22.53M
$34.96M
Total operating expenses
$115M
$108.96M
$108.79M
$102.85M
$101.12M
$107.67M
$98.58M
$107.14M
Operating income
$4.35M
$9.67M
$526K
$2.49M
$208K
-$6.19M
-$5.95M
-$14.52M
Interest expense
-$1.61M
-$1.32M
-$1.34M
-$1.5M
-$1.47M
-$1.49M
-$1.42M
-$1.45M
Income before taxes
$4.02M
$9.43M
$394K
$2.36M
-$86K
-$5.93M
-$6.51M
-$15.3M
Income taxes
-$47K
$471K
$286K
$604K
$181K
$261K
$239K
$266K
Net income
$4.06M
$8.96M
$108K
$1.76M
-$267K
-$6.19M
-$6.75M
-$15.57M
Net income attributable to common shareholders
$4.06M
$8.96M
$108K
$1.76M
-$267K
-$6.19M
-$6.75M
-$15.57M
EBITDA
$9.83M
$14.97M
$5.8M
$7.6M
$5.38M
-$1.02M
-$870K
-$9.7M
Basic earnings per share
$0.08
$0.18
$0.00
$0.04
-$0.01
-$0.13
-$0.14
-$0.33
Diluted earnings per share
$0.08
$0.18
$0.00
$0.04
-$0.01
-$0.13
-$0.14
-$0.33
Recent news
Company coverage with links to the original publishers.
The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.
AtriCure director Maggie Yuen sold 3,500 shares (20% of her stake) at $38.42 per share on August 5, 2026, totaling $134,470. The sale occurred after the company reported strong Q2 results with 13% revenue growth to $154 million and expanded gross margins to 77%. The stock has surged over 60% since June lows, and analysts suggest the director sales likely reflect a post-earnings trading window opening rather than loss of confidence in the company.
AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares valued at $377,000, representing a significant portion of his holdings. Despite the sale, the company shows potential with 16% year-over-year sales growth and improving financial metrics.
Questex's Fierce Healthcare announces the finalists of the second annual Fierce DEI Awards, which celebrate outstanding achievements in Diversity, Equity, and Inclusion within the healthcare industry. The finalists include organizations, initiatives, and individuals recognized for their contributions to creating a more equitable and inclusive healthcare environment.
AtriCure, a medical device company, has received approval from China's National Medical Products Administration to market its AtriClip Left Atrial Appendage Exclusion System in China. This is a key development in the company's global expansion strategy, as China represents a significant market opportunity.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.